Evidence map›Paper›PMID 41472485›Full record

ReviewAddiction (Abingdon, England)2026

Addiction-related problems in Japan: A regional perspective.

Soichiro Ide, Yoko Nishitani, Masahiko Sumitani, Masabumi Minami, Tadashi Isa, Masako Iseki, Michiko Ohkura, Hitoshi Okamoto, Tetsuro Kikuchi, Yuko Sekino and 10 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Soichiro IdeAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID 0000-0002-9112-2841
Yoko NishitaniDepartment of Forensic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Masahiko SumitaniDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Masabumi MinamiDepartment of Pharmacology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Tadashi IsaDepartment of Neurobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Masako IsekiDepartment of Anesthesiology and Pain Clinic, Juntendo University Faculty of Medicine, Tokyo, Japan.
Michiko OhkuraResearch and Development Initiative, Chuo University, Tokyo, Japan.
Hitoshi OkamotoRIKEN Center for Brain Science, Saitama, Japan.
Tetsuro KikuchiOtsuka Pharmaceutical Co., Ltd., Tokushima, Japan.
Yuko SekinoGraduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, Japan.
Hidehiko TakahashiGraduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
Kenji TakeuchiKyushu University Faculty of Law, Fukuoka, Japan.
Atsumi NittaDepartment of Pharmaceutical Therapy & Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Takeshi HonjoHitotsubashi University Graduate School of Law, Tokyo, Japan.
Hiroshi MatsumotoThe Institute for Death Control and Prevention, The University of Osaka, Osaka, Japan.
Tsuyoshi MiyakawaDivision of Systems Medical Science, Center for Medical Science, Fujita Health University, Aichi, Japan.
Toshiya MuraiDepartment of Psychiatry, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toshihiko MatsumotoDepartment of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
Kazuyuki NakagomeDepartment of Psychiatry, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID 0000-0001-8342-0278

Funding

Japan Society for the Promotion of Science 24 K10049Japan Society for the Promotion of Science 24K10049Multilayered Stress Diseases JPMXP1323015483
6 · The paper itself

Abstract

Japan's addiction landscape appears paradoxical. The lifetime use of illicit drugs is among the lowest in Organisation for Economic Cooperation and Development countries, but harm from alcohol, tobacco, and gambling ranks among the world's highest. Historically, methamphetamine accounted for the majority of drug-related offenses, but the number of people who were apprehended for cannabis offenses in 2023 exceeded the number who were apprehended for stimulants for the first time since 1958. Nevertheless, the lifetime prevalence of illicit drug use among adults remains under ~3%. In contrast, heavy drinking among working-age men, decades of tobacco consumption, and rapid digitalization that has more recently led to a surge in online gambling and gaming disorder have imposed a substantial disease burden. The present review discusses Japan's epidemiology, social impact, policy changes, prevention, and treatment infrastructure of drug-related problems and the latest trends in addiction science and proposes ways to link policy and research. Japan's experience, balancing strict enforcement with health-centered care, may offer lessons for regions that have similar social contexts.

Indexed as

Behavior, AddictiveSubstance-Related DisordersAdultGamblingHumansJapanMalePrevalenceaddictionalcoholcannabisgamblingjapantobacco

Identifiers

PMID41472485
PMCPMC13088920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.